BIT's 17th Annual Congress of International Drug Discovery Science and Technology (IDDST-2019)

Conference Report of IDDST-2019

BIT's 17^th Annual Congress of International Drug Discovery Science and Technology-2019 (IDDST-2019) which was held in Kyoto International Conference Center on July 25-27, achieved a consummation. Our conference was hosted by BIT Group Global Ltd., supported by Japan Pharmaceutical Manufacturers Association, Axcelead Drug Discovery Partners, Inc., UK Pharmacogenetics and Stratified Medicine Network, The Czech Pharmaceutical Society and The Center for the Biology of Chronic Disease. Over 300 honored guests presented at the ceremony and gave brilliant speeches on invitation, among them are Dr. Xiaodan Mei, President, BIT Group Global Ltd., China; Dr. Yoshinori Ikeura, CEO, Axcelead Drug Discovery Partners, Inc., Japan; Dr. Matthias von Herrath, Professor, La Jolla Institute; Vice President, NovoNordisk, USA; Dr. Zhuo Li, General Manager, NanoTemper Technologies, China; Dr. Kazuhide Inoue, EVP & Professor, Kyushu University, Japan; Dr. Loui Madakamutil, SVP, Head of Discovery, Nektar Therapeutics, USA; Dr. Michael Gamlen, Chief Scientific Officer, Gamlen Tableting Ltd., UK…etc.

This annual congress comprised of 30 sessions following the ceremony, including “Drug Discovery S & T “, “Breaking Preclinical and Clinical Research"; “Last Stage Drug Discovery"; “New Biotherapy Discovery"…etc.

This annual conference brought together 400 specialists from 36 countries and areas, which was devoted to the leading issues and popular topics and provide up-to-date information to all over the world. In welcome banquet, all guests appreciated and joined in the brilliant Japanese traditional performances, also expressed sincerely congratulation to successful IDDST-2019. Depending on the warmly support and good suggestions from all of the participants, we are quite confident in organizing IDDST-2020 which would be better and more successful. All of us are looking forward to meeting you again in 2020.

Program at a Glance

Stream 1: Keynote Forum
Stream 2: Drug Discovery S & T	Stream 4: Last Stage Drug Discovery
Stream 3: Breaking Preclinical and Clinical Research	Stream 5: Posters and Exhibition

Keynote Speakers

	Dr. Yoshinori Ikeura, CEO/CSO, Axcelead Drug Discovery Partners, Inc., Japan		Dr. Matthias von Herrath, Professor, La Jolla Institute; Vice President, NovoNordisk, USA
	Dr. Kazuhide Inoue, Professor, Kyushu University, Japan		Dr. Loui Madakamutil, SVP, Head of Discovery, Nektar Therapeutics, USA
	Dr. Michael Gamlen, Chief Scientific Officer, Gamlen Tableting Ltd., UK		Dr. Zhuo Li, General Manager, NanoTemper Technologies, China

Confirmed Renowned Speakers

Dr. Benno Rattel, Executive Director, Nonclinical Development, Amgen Research, Germany	Dr. Jonathan Zalevsky, Senior Vice President, CSO, Research, Nektar Therapeutics, USA	Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France
Dr. Tord Labuda, Vice President R&D, LEO Pharma K.K., Japan	Dr. Le Sun, President, AbMax Biotechnology Co., Ltd., China	Dr. Angelito Jonas L. Kalaw, Medical Director, PAREXEL International, Australia
Dr. Balazs Sarkadi, Professor, Semmelweis University, Hungary	Dr. Laszlo Takacs, Professor, University of Debrecen, Hungary	Dr. Yukio Yoneda, Professor Emeritus, Kanazawa University, Japan
Dr. Anthony W. Coleman, Research Director, Université de Lyon, France	Dr. James Legg, Vice President, Research and Development, Crescendo Biologics Ltd., UK	Dr. Meredith Rocca,Senior Scientific Director, Biologics Toxicology, Janssen R & D, USA
Dr. Mircea Ciuca, Global Head Medical & Clinical Drug Safety, Vifor Pharma, Switzerland	Dr. Amrik Basran, CSO, Avacta Life Sciences, UK	Dr. Frank S. Walsh, CEO, Ossianix, Inc., USA
Dr. Karol Jackowski, Professor of Chemistry, University of Warsaw, Poland	Dr. Hiroshi Maruta, Professor, PAK Research Center, Australia	Dr. Yaakov Naparstek, Professor of Medicine, Hadassah University Hospital, Israel
Dr. Richard C Bethell, Chief Scientific Officer, Medivir AB, Sweden	Dr. Aruna Dontabhaktuni, President & CEO, PharmaPro Consulting, USA	Dr. Maria Fardis, President & CEO, Iovance Biotherapeutics, USA
Dr. Richard Denk, Head Sales Containment, SKAN AG, Switzerland	Dr. Robert S. Plumb, Director Omics Sciences, Scientific Operations, Waters Corporation, USA	Dr. Graham R. Ball, Professor/CSO, Nottingham Trent University/CompanDX, UK
Dr. Ilya B. Tsyrlov, President and CSO, Xenotox Inc, USA	Dr. Jacintha Shenton, Scientific Director, Biologics Toxicology, Janssen R&D, USA	Dr. Maier C William, CSO, ICON PLC, UK
Dr. Kang Li, Head of Biologics, BeiGene, China	Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany	Dr. Eiichi Saitoh, Professor, Niigata Institute of Technology, Japan
Dr. Domingo Gargallo-Viola, CSO, ABAC Therapeutics, Spain	Dr. Lee Gethings, Senior Manager, Waters Corporation, UK	Dr. Gail Adinamis, CEO, GlobalCare Clinical Trials, Ltd., USA
Dr. Yinsheng Zhang, Senior Director, Chia Tai Tianqing Pharmaceutical Group Co.,China	Dr. Xiao Feng, President of R&D Center, GeneScience Pharmaceuticals Co., Ltd, China	Dr. Jeffrey Hung, CCO and GM, Vigene Biosciences, USA

Scenery of Kyoto

Kyoto, literally "Capital City", is a city located in the central part of the island of Honshu, Japan. It has a population close to 1.5 million. Kyoto is the most well known capital of Japan in Japanese history for more than one thousand years, it is now the capital city of Kyoto Prefecture located in the Kansai region, as well as a major part of the Kyoto-Osaka-Kobe metropolitan area.

Conference Guide